Benzydamine inhibits osteoclast differentiation and bone resorption via down-regulation of interleukin-1β expression
Bone diseases such as osteoporosis and periodontitis are induced by excessive osteoclastic activity, which is closely associated with inflammation. Benzydamine (BA) has been used as a cytokine-suppressive or non-steroidal anti-inflammatory drug that inhibits the production of pro-inflammatory cytoki...
Gorde:
| Egile Nagusiak: | , , , , , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Elsevier
2020-03-01
|
| Saila: | Acta Pharmaceutica Sinica B |
| Sarrera elektronikoa: | http://www.sciencedirect.com/science/article/pii/S2211383519303132 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|